AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31888711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 28507353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-Propofol
Number of subjects: 60
Study 28507353 — intervention group
Group type: COMPARATOR
Intervention: Ketamine-Dexmedetomidine
Number of subjects: 60
Study 25731132 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention targeting cognitive dysfunction, including education on cognitive function, self-awareness training, compensatory strategies, and problem-solving therapy; formal working memory training in a subgroup.
Number of subjects: 16
Study 24083804 — intervention group
Group type: EXPERIMENTAL
Intervention: eplerenone (target dose 50mg)
Number of subjects: 130
Study 24083804 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 130
Study 21242700 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute resistance exercise protocol (6 sets of 5 repetition maximum heavy squats)
Number of subjects: 15
Study 21242700 — intervention group
Group type: COMPARATOR
Intervention: Control test
Number of subjects: 15
Study 21242700 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute resistance exercise protocol
Number of subjects: 15
Study 19513028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation (RBL)
Number of subjects: 45
Study 19513028 — intervention group
Group type: COMPARATOR
Intervention: Bipolar Electrocoagulation (BPEC)
Number of subjects: 45
Study 18372688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent artificial gravity (AG)
Number of subjects: 15
Study 18372688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no artificial gravity)
Number of subjects: 15
Study 14691037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 958
Study 14691037 — intervention group
Group type: COMPARATOR
Intervention: Bare stents (pre-SES group)
Number of subjects: 958
Study 12153921 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials funded by for profit organisations alone
Number of subjects: 159
Study 12153921 — intervention group
Group type: COMPARATOR
Intervention: Trials without competing interests
Number of subjects: 159
Study 12153921 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials funded by both for profit and non‐profit organisations
Number of subjects: 159
Study 12153921 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with other competing interests
Number of subjects: 159
Study 12153921 — intervention group
Group type: COMPARATOR
Intervention: Other competing interests and funding from both for profit and non‐profit organisations
Number of subjects: 159
Study 9833847 — intervention group
Group type: COMPARATOR
Intervention: 100 mg abacavir twice daily
Number of subjects: 60
Study 9833847 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg abacavir twice daily
Number of subjects: 60
Study 9833847 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg abacavir twice daily
Number of subjects: 60
Study 9833847 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg abacavir + zidovudine + lamivudine (open-label phase)
Number of subjects: 60
Study 9833847 — intervention group
Group type: EXPERIMENTAL
Intervention: All abacavir-treated subjects (pooled data)
Number of subjects: 60
Study 9833847 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (overall safety)
Number of subjects: 60
Study 8135426 — intervention group
Group type: EXPERIMENTAL
Intervention: IV phenytoin (15 mg/kg over 20 minutes)
Number of subjects: 147
Study 8135426 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo (equivalent volume over 20 minutes)
Number of subjects: 147
Study 2552625 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored 3 to 8 days
Number of subjects: 166
Study 2552625 — intervention group
Group type: COMPARATOR
Intervention: RBCs stored 20 to 42 days
Number of subjects: 166
Study 2552625 — intervention group
Group type: EXPERIMENTAL
Intervention: Seronegative RBCs
Number of subjects: 166
Study 2552625 — intervention group
Group type: COMPARATOR
Intervention: Random RBCs
Number of subjects: 166
Study 162671 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac sodium
Number of subjects: 32
Study 162671 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 31642694 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CCTA) with standard care
Number of subjects: 0
Study 31642694 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 30695668 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Letrozole
Number of subjects: 0
Study 30695668 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 0
Study 28027625 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (n = 359)
Number of subjects: 715
Study 28027625 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin Inhibitor (CNI) (n = 356)
Number of subjects: 715
Study 28027625 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (part of CNI group)
Number of subjects: 715
Study 28027625 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (part of CNI group)
Number of subjects: 715
Study 25932981 — intervention group
Group type: EXPERIMENTAL
Intervention: TOTAL (3 days per week using a total-body routine)
Number of subjects: 20
Study 25932981 — intervention group
Group type: COMPARATOR
Intervention: SPLIT (1 day per week using a split-body routine)
Number of subjects: 20
Study 24500150 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM-supplemented, low-energy, low-protein experimental formula (EF)
Number of subjects: 240
Study 24500150 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 240
Study 24500150 — intervention group
Group type: COMPARATOR
Intervention: Breastfed reference (BFR) group
Number of subjects: 240
Study 22929331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary perifissural nodules (PFNs) identified via CT scans
Number of subjects: 2994
Study 19957560 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaferon 8MIU subcutaneously every other day (Group A)
Number of subjects: 55
Study 19957560 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaferon with a reduced dosage regimen (2 MIU, 4 MIU, and 8 MIU) subcutaneously, varying by week (Group B)
Number of subjects: 55
Study 17601993 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox treatment
Number of subjects: 9
Study 17601993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 16366421 — intervention group
Group type: EXPERIMENTAL
Intervention: HCA-SX 4,667 mg (providing 2,800 mg HCA per day)
Number of subjects: 90
Study 16366421 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HCA-SX 4,667 mg, niacin-bound chromium (NBC) 4 mg, and Gymnema sylvestre extract (GSE) 400 mg
Number of subjects: 90
Study 16366421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12228880 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 12228880 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 12228880 — intervention group
Group type: COMPARATOR
Intervention: Unclassified group
Number of subjects: 0
Study 9476870 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Flow Monitoring (PFM)
Number of subjects: 92
Study 9476870 — intervention group
Group type: COMPARATOR
Intervention: Symptoms Group
Number of subjects: 92
Study 7624991 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin, 3.6 mg every 28 days
Number of subjects: 283
Study 7624991 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 283
Study 2793646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 189
Study 2793646 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid
Number of subjects: 189
Study 343863 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine for 12 weeks
Number of subjects: 64
Study 343863 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 64
Study 29363136 — intervention group
Group type: EXPERIMENTAL
Intervention: Finisher GF Brush (GB)
Number of subjects: 72
Study 29363136 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe-and-needle irrigation (SNI)
Number of subjects: 72
Study 29363136 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated canals)
Number of subjects: 72
Study 27343785 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope™ visualization
Number of subjects: 96
Study 27343785 — intervention group
Group type: COMPARATOR
Intervention: MacIntosh laryngoscope assistance
Number of subjects: 96
Study 24507744 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ablation (SA)
Number of subjects: 194
Study 24507744 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical ablation (non-SA)
Number of subjects: 194
Study 24507744 — intervention group
Group type: EXPERIMENTAL
Intervention: History of myocardial infarction
Number of subjects: 194
Study 24507744 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher EuroSCORE
Number of subjects: 194
Study 22278004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 0
Study 22278004 — intervention group
Group type: EXPERIMENTAL
Intervention: Other psychotherapeutic methods
Number of subjects: 0
Study 20155571 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted to deep water running
Number of subjects: 17
Study 20155571 — intervention group
Group type: COMPARATOR
Intervention: Not adapted to deep water running
Number of subjects: 17
Study 20155571 — intervention group
Group type: COMPARATOR
Intervention: Treadmill running
Number of subjects: 17
Study 20155571 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep water running
Number of subjects: 17
Study 18621453 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week biomechanical ankle platform system training
Number of subjects: 12
Study 16023214 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment for high-risk prethreshold ROP (n = 317 eyes)
Number of subjects: 401
Study 16023214 — intervention group
Group type: COMPARATOR
Intervention: Conventional management for high-risk prethreshold ROP (n = 307 eyes)
Number of subjects: 401
Study 16023214 — intervention group
Group type: COMPARATOR
Intervention: Conventional management when threshold ROP developed
Number of subjects: 401
Study 16023214 — intervention group
Group type: COMPARATOR
Intervention: Conventional management when regression without treatment occurred
Number of subjects: 401
Study 16023214 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment at high-risk prethreshold ROP with abnormal angle of temporal retinal vessels or macular ectopia
Number of subjects: 401
Study 16023214 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment at high-risk prethreshold ROP with no retinal residua
Number of subjects: 401
Study 16023214 — intervention group
Group type: COMPARATOR
Intervention: Conventional management with abnormal angle of temporal retinal vessels or macular ectopia
Number of subjects: 401
Study 16023214 — intervention group
Group type: COMPARATOR
Intervention: Conventional management with no retinal residua
Number of subjects: 401
Study 11920310 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose IFN
Number of subjects: 22
Study 10334540 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP 50 mg/m2, GEM 1,000 mg/m2, and VNR 25 mg/m2 on days 1 and 8 of an every-3-weeks cycle (arm A)
Number of subjects: 111
Study 10334540 — intervention group
Group type: COMPARATOR
Intervention: CDDP 80 mg/m2, epirubicin 80 mg/m2, and vindesine 3 mg/m2 on day 1 every 4 weeks, plus lonidamine orally 150 mg three times daily (arm B)
Number of subjects: 111
Study 10334540 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP-GEM-VNR combination (arm A)
Number of subjects: 111
Study 10334540 — intervention group
Group type: COMPARATOR
Intervention: CDDP-epirubicin-vindesine-lonidamine combination (arm B)
Number of subjects: 111
Study 8603548 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic rectopexy
Number of subjects: 0
Study 1669483 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/ml (0.5%) timolol maleate
Number of subjects: 64
Study 1669483 — intervention group
Group type: COMPARATOR
Intervention: No drugs (comparison group)
Number of subjects: 64
Study 7079067 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat condition (cortical temperature raised by 7 degrees F)
Number of subjects: 6
Study 7079067 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (helmet with no external heat applied)
Number of subjects: 6
Study 7079067 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific details provided)
Number of subjects: 6
Study 31529194 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevena™ negative pressure wound therapy
Number of subjects: 271
Study 31529194 — intervention group
Group type: EXPERIMENTAL
Intervention: PICO™ negative pressure wound therapy
Number of subjects: 271
Study 31529194 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressings (control)
Number of subjects: 271
Study 28273318 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA) plus low vision rehabilitation with an occupational therapist (OT‐LVR)
Number of subjects: 188
Study 28273318 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 188
Study 26093032 — intervention group
Group type: EXPERIMENTAL
Intervention: RUL Brief Pulse (BP) ECT (1.0 ms)
Number of subjects: 87
Study 26093032 — intervention group
Group type: EXPERIMENTAL
Intervention: RUL Ultrabrief Pulse (UBP) ECT (0.3-0.4 ms)
Number of subjects: 87
Study 24446026 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Cediranib
Number of subjects: 12
Study 24446026 — intervention group
Group type: COMPARATOR
Intervention: Delayed Cediranib
Number of subjects: 12
Study 22825366 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-celiac wheat sensitivity (WS) diagnosed by double-blind placebo-controlled challenge
Number of subjects: 276
Study 22825366 — intervention group
Group type: COMPARATOR
Intervention: Celiac disease (CD) patients
Number of subjects: 276
Study 22825366 — intervention group
Group type: COMPARATOR
Intervention: Irritable bowel syndrome (IBS) patients
Number of subjects: 276
Study 19569890 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 0
Study 17766764 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported insight
Number of subjects: 67
Study 17766764 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported insight (awareness of illness dimension)
Number of subjects: 67
Study 15080377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 1650
Study 15080377 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 1650
Study 12053331 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute compression (group 1)
Number of subjects: 130
Study 12053331 — intervention group
Group type: COMPARATOR
Intervention: 15-minute compression (group 2)
Number of subjects: 130
Study 9491788 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD1694 (Tomudex®)
Number of subjects: 0
Study 9491788 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan (Campto®)
Number of subjects: 0
Study 9491788 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaliplatin (L-OHP®) in combination with continuous infusion 5-FU
Number of subjects: 0
Study 7857999 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of weekly sessions of supervised group physical therapy
Number of subjects: 68
Study 7857999 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised daily exercises at home (discontinuation group)
Number of subjects: 68
Study 2892520 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam elixir 30 mg by mouth
Number of subjects: 50
Study 2892520 — intervention group
Group type: COMPARATOR
Intervention: Diazemuls i.v. titrated to a maximum dose of 20 mg
Number of subjects: 50
Study 31308848 — intervention group
Group type: EXPERIMENTAL
Intervention: Left anodal tDCS
Number of subjects: 0
Study 31308848 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anodal tDCS
Number of subjects: 0
Study 31308848 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 28359279 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume irrigation (HV)
Number of subjects: 300
Study 28359279 — intervention group
Group type: COMPARATOR
Intervention: Low-volume irrigation (LV)
Number of subjects: 300
Study 26187303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Insulin Titration Intervention (MITI) using SMS text messages and phone calls
Number of subjects: 61
Study 26187303 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (standard clinic care for insulin titration)
Number of subjects: 61
Study 26187303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Insulin Titration Intervention (MITI)
Number of subjects: 61
Study 26187303 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 61
Study 22835990 — intervention group
Group type: COMPARATOR
Intervention: Self-reported depressive symptoms (BDI score ≥ 19)
Number of subjects: 2704
Study 22835990 — intervention group
Group type: COMPARATOR
Intervention: Clinical depression
Number of subjects: 2704
Study 17145434 — intervention group
Group type: EXPERIMENTAL
Intervention: External valvuloplasty of the femoral vein combined with surgery of the superficial venous system (Group A)
Number of subjects: 40
Study 17145434 — intervention group
Group type: COMPARATOR
Intervention: Surgery of the superficial venous system alone (Group B)
Number of subjects: 40
Study 12705569 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from stigmatized ethnic groups aware of broadly held stereotypes
Number of subjects: 202
Study 12705569 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from academically stigmatized ethnic groups (African Americans and Latinos)
Number of subjects: 202
Study 12705569 — intervention group
Group type: EXPERIMENTAL
Intervention: Children ages 6 to 10
Number of subjects: 202
Study 10551711 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-J rectilinear biphasic shock
Number of subjects: 184
Study 10551711 — intervention group
Group type: COMPARATOR
Intervention: 200-J damped sine wave monophasic shock
Number of subjects: 184
Study 8901852 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of tamoxifen
Number of subjects: 3545
Study 8901852 — intervention group
Group type: COMPARATOR
Intervention: 2 years of tamoxifen
Number of subjects: 3545
Study 1687131 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 12.5 micrograms b.d.
Number of subjects: 692
Study 1687131 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms b.d.
Number of subjects: 692
Study 1687131 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms b.d.
Number of subjects: 692
Study 1687131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study 6336975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol pretreatment (300 mg two hours prior to and 10 hours after 5-FU)
Number of subjects: 23
Study 6336975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol pretreatment (300 mg every 8 hours for 4 doses starting 24 hours before 5-FU)
Number of subjects: 23
Study 6336975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol pretreatment
Number of subjects: 23
Study 6336975 — intervention group
Group type: COMPARATOR
Intervention: 5-FU administration
Number of subjects: 23
Study 31141410 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with and Caring for infants with special needs (COPCA)
Number of subjects: 43
Study 31141410 — intervention group
Group type: COMPARATOR
Intervention: Typical infant physiotherapy
Number of subjects: 43
Study 30926996 — intervention group
Group type: EXPERIMENTAL
Intervention: School Feeding Program (SFP) providing multiple-micronutrient-fortified meals
Number of subjects: 627
Study 30926996 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-Home Ration (THR) nutritionally equivalent to SFP
Number of subjects: 627
Study 30926996 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-Home Ration (THR)
Number of subjects: 627
Study 30926996 — intervention group
Group type: EXPERIMENTAL
Intervention: School Feeding Program (SFP)
Number of subjects: 627
Study 30926996 — intervention group
Group type: COMPARATOR
Intervention: Control group with no FFE
Number of subjects: 627
Study 28372046 — intervention group
Group type: EXPERIMENTAL
Intervention: Word recognition training with target and masker differing in gender
Number of subjects: 0
Study 28372046 — intervention group
Group type: EXPERIMENTAL
Intervention: Word recognition training with same‐gender target and masker
Number of subjects: 0
Study 28372046 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender recognition training
Number of subjects: 0
Study 28372046 — intervention group
Group type: COMPARATOR
Intervention: Control with no training
Number of subjects: 0
Study 26443653 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths Model Case Management (SMCM)
Number of subjects: 86
Study 26443653 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched control)
Number of subjects: 86
Study 23622444 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier treated eyes (high-risk prethreshold ROP)
Number of subjects: 401
Study 23622444 — intervention group
Group type: COMPARATOR
Intervention: Conventionally managed eyes (treatment only if threshold ROP developed)
Number of subjects: 401
Study 20725062 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (Teavigo) 135 mg/capsule, 3 capsules/day for 48 hours
Number of subjects: 16
Study 20725062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20725062 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (Teavigo)
Number of subjects: 16
Study 19458432 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulated middle frequency alternating current (MFAC) stimulation
Number of subjects: 13
Study 19458432 — intervention group
Group type: COMPARATOR
Intervention: Standard low frequency rectangular pulse (LFRP) stimulation
Number of subjects: 13
Study 17123343 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIAC 0.1%
Number of subjects: 39
Study 17123343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39